Bioassociate Consulting
Long/short equity, value, event-driven, long only

BioLine Is Approaching Its Moment Of Truth

BioLineRx (NASDAQ:BLRX) is about to face one of its defining moments in 1Q 2013, when results of an interim analysis from the phase 2/3 CLARITY study of BL-1020 are expected to be released. BL-1020, BioLine's leading drug candidate, is an orally available GABA-enhanced antipsychotic for the treatment of both the positive an...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
  • Access Top Ideas, chosen by Seeking Alpha’s editors
  • Filter long and short ideas by market cap and sector
  • Get Coverage of over 5,000 stocks, many of which have little or no coverage elsewhere
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO." Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else." Patrick Rice, Mainstay Capital Management
100% Satisfaction Guaranteed
You are protected by the Seeking Alpha Money Back Guarantee and will get a prompt refund on the unused portion of your subscription at any time, for any reason.